| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZD8055 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.08 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | -0.051 | 0.08 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.084 | 0.08 |
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | -0.053 | 0.08 |
| mRNA | PFI-1 | GDSC1000 | pan-cancer | AAC | 0.057 | 0.08 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.062 | 0.08 |
| mRNA | KIN001-236 | GDSC1000 | pan-cancer | AAC | -0.057 | 0.08 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.08 | 0.08 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | -0.063 | 0.08 |
| mRNA | BMS-509744 | GDSC1000 | pan-cancer | AAC | 0.086 | 0.09 |